Collecting information on redifferentiating medications for thyroid cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather data on the use of redifferentiating medications as a standard treatment for patients with radioactive iodine (RAI)-refractory thyroid cancer. It will involve patients who are either newly receiving these medications or have previously been treated with them in a clinical setting. The study will track the outcomes of these patients as they undergo routine clinical care, specifically focusing on their responses to subsequent RAI therapy. By creating a registry, the study seeks to enhance understanding of the effectiveness of redifferentiation agents in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients ≥ 18 years old at time of consent

Inclusion Criteria:

* Patients diagnosed with RAI refractory thyroid cancer or unlikely to respond to RAI.
* Patients who will receive redifferentiation agents prior to planned diagnostic and/or therapeutic use of radioactive iodine as part of routine clinical care.
* Patients who have never received redifferentiation agents outside of a clinical trial or have received redifferentiation agents in the context of a clinical trial will be enrolled after the clinical team has decided to proceed with a redifferentiation agent as part of routine clinical care prior to diagnostic and/or therapeutic radioactive iodine administration.
* Patients previously treated with redifferentiation agents as part of clinical care prior to diagnostic and/or therapeutic radioactive iodine administration who are willing to provide retrospectively collected data surrounding the time of the previous treatment and will provide prospective data from the time of consent.

Exclusion Criteria:

* RAI refractory thyroid cancer patients that will receive redifferentiation agents prior to diagnostic and/or therapeutic use of radioactive iodine as part of a prospective clinical trial.

Where it's running

• Memorial Sloan Kettering Cancer Center
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Laura Boucai, MD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Laura Boucai, MD
• Email: boucail@mskcc.org
• Phone: 646-608-3906

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Optimizing Levothyroxine Dosage for Patients After Thyroid Surgery

  This study is testing a new tool that helps find the right dose of levothyroxine faster for people who have had their thyroid removed, to see if it improves their health and ability to work compared to regular care.

  Recruiting at 3 sites University Hospital of North Norway · Bergen and 2 other locations · NCT06455371

• MRG003 added to ongoing treatment after progression in EGFR-positive advanced thyroid cancer

  In this study, researchers test whether adding MRG003 to a patient’s current thyroid cancer treatment can shrink tumors for those whose cancer initially responded but later progressed.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07874321

• Selective coverage radiotherapy vs. full coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer

  This trial tests whether covering only the tumor-affected area with radiation is as effective as full-area coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer, while aiming to reduce side effects and improve quality of life.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07777536

• Trop-2 Targeted PET/CT for Recurrent and Metastatic Thyroid Cancer

  This study tests whether a Trop-2 targeted PET/CT scan can better detect recurrent or metastatic thyroid cancer in adults than another PET/CT scan (FAPI).

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07753499

• WeChat-supported neck exercises after thyroidectomy

  A telehealth program using a WeChat mini program tests if guided neck exercises after thyroid surgery help early recovery and quality of life.

  Recruiting Shanghai 6th People's Hospital · Shanghai, Shanghai Municipality · NCT07707401

• Pralsetinib Drug Interaction Study in RET Fusion/MUTATION Positive Solid Tumors

  This trial tests whether pralsetinib changes how the body processes certain medicines in adults with RET fusion- or mutation-positive advanced solid tumors.

  Recruiting at 2 sites Phase 4 Rigel Pharmaceuticals · Logroño, La Rioja and 1 other locations · NCT07704658

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.